CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million

By Public Technologies
  • Aquestive Therapeutics forecasts 2026 revenue of $46 million-$50 million in its November 3 outlook.
  • Non-GAAP adjusted EBITDA loss is projected at $30 million-$35 million.
  • Third-quarter cash totaled $90.3 million, down from $98.5 million in the second quarter.
  • An October Libervant out-licensing deal generated $10 million upfront, with potential contingent milestone payments totaling $47.5 million.
  • Anaphylm’s potential launch is targeted for the second quarter of 2027, subject to FDA approval; its review goal date is March 16.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aquestive Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk